Patents by Inventor Thomas Bohnacker
Thomas Bohnacker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20260345602Abstract: The present invention is inter alia concerned with (i) a combination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for use in the treatment of a patient suffering from cancer, wherein the cancer exhibits an oncogenic alteration in the KRAS; (ii) a kit comprising (a) a pharmaceutical dosage form comprising a CBP/p300 bromodomain inhibitor and (b) a pharmaceutical dosage form comprising a KRAS inhibitor; and (iii) a pharmaceutical dosage form comprising a CBP/p300 bromodomain inhibitor and a KRAS inhibitor.Type: ApplicationFiled: October 20, 2025Publication date: November 5, 2026Applicant: TOLREMO THERAPEUTICS AGInventors: Stefanie Flückiger-Mangual, Dorothea Gruber, Thomas Bohnacker, Martin Schwill, Debora Schmitz-Rohmer, Charles-Henry Fabritius, Sara Laudato
-
Publication number: 20260297078Abstract: The present invention relates to compounds of formula (I) or salts, solvates, cocrystals, tautomers, or mixtures thereof. Furthermore, the present invention relates to pharmaceutical compositions comprising said compounds. Moreover, the present invention relates to the compounds of formula (I) or the salts, solvates, cocrystals, tautomers, or mixtures thereof or the pharmaceutical compositions for use as a medicament and to the compounds of formula (I) or the salts, solvates, cocrystals, tautomers, or mixtures thereof or the pharmaceutical compositions for use in the treatment or amelioration of cancer. Optionally, the compounds of formula (I) or the salts, solvates, cocrystals, tautomers, or mixtures thereof or the pharmaceutical compositions are administered in combination with a second therapeutic agent, in particular an anti-cancer agent.Type: ApplicationFiled: March 6, 2026Publication date: October 1, 2026Inventors: Charles-Henry Fabritius, Koen Hekking, Dorothea Gruber, Rutger Folmer, Stefanie Flückiger-Mangual, Thomas Bohnacker, Martin Schwill, Debora Schmitz-Rohmer
-
Patent number: 12648947Abstract: The present invention relates to a compound of formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof and to pharmaceutical compositions comprising a compound of formula (I), as well as to the use of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, in the treatment of fibrotic diseases, preferably idiopathic pulmonary fibrosis (IPF) or non-alcoholic steatohepatitis (NASH). Further aspects of the present invention include combination therapies in which a compound of formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, is used in combination with a known anti-fibrotic or anti-inflammatory agents for fibrotic diseases.Type: GrantFiled: June 24, 2021Date of Patent: June 9, 2026Assignee: Tolremo Therapeutics AGInventors: Stefanie Flückiger-Mangual, Thomas Bohnacker
-
Patent number: 12595258Abstract: The present invention relates to compounds of formula (I) or salts, solvates, cocrystals, tautomers, or mixtures thereof. Furthermore, the present invention relates to pharmaceutical compositions comprising said compounds. Moreover, the present invention relates to the compounds of formula (I) or the salts, solvates, cocrystals, tautomers, or mixtures thereof or the pharmaceutical compositions for use as a medicament and to the compounds of formula (I) or the salts, solvates, cocrystals, tautomers, or mixtures thereof or the pharmaceutical compositions for use in the treatment or amelioration of cancer. Optionally, the compounds of formula (I) or the salts, solvates, cocrystals, tautomers, or mixtures thereof or the pharmaceutical compositions are administered in combination with a second therapeutic agent, in particular an anti-cancer agent.Type: GrantFiled: April 15, 2025Date of Patent: April 7, 2026Assignee: Tolremo Therapeutics AGInventors: Charles-Henry Fabritius, Koen Hekking, Dorothea Gruber, Rutger Folmer, Stefanie Flückiger-Mangual, Thomas Bohnacker, Martin Schwill, Debora Schmitz-Rohmer
-
Patent number: 12472179Abstract: The present invention is inter alia concerned with (i) a combination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for use in the treatment of a patient suffering from cancer, wherein the cancer exhibits an oncogenic alteration in the KRAS; (ii) a kit comprising (a) a pharmaceutical dosage form comprising a CBP/p300 bromodomain inhibitor and (b) a pharmaceutical dosage form comprising a KRAS inhibitor, and (iii) a pharmaceutical dosage form comprising a CBP/p300 bromodomain inhibitor and a KRAS inhibitor.Type: GrantFiled: June 24, 2021Date of Patent: November 18, 2025Assignee: Tolremo Therapeutics AGInventors: Stefanie Flückiger-Mangual, Dorothea Gruber, Thomas Bohnacker, Martin Schwill, Debora Schmitz-Rohmer, Charles-Henry Fabritius, Sara Laudato
-
Publication number: 20250243191Abstract: The present invention relates to compounds of formula (I) or salts, solvates, cocrystals, tautomers, or mixtures thereof. Furthermore, the present invention relates to pharmaceutical compositions comprising said compounds. Moreover, the present invention relates to the compounds of formula (I) or the salts, solvates, cocrystals, tautomers, or mixtures thereof or the pharmaceutical compositions for use as a medicament and to the compounds of formula (I) or the salts, solvates, cocrystals, tautomers, or mixtures thereof or the pharmaceutical compositions for use in the treatment or amelioration of cancer. Optionally, the compounds of formula (I) or the salts, solvates, cocrystals, tautomers, or mixtures thereof or the pharmaceutical compositions are administered in combination with a second therapeutic agent, in particular an anti-cancer agent.Type: ApplicationFiled: April 15, 2025Publication date: July 31, 2025Inventors: Charles-Henry Fabritius, Koen Hekking, Dorothea Gruber, Rutger Folmer, Stefanie Flückiger-Mangual, Thomas Bohnacker, Martin Schwill, Debora Schmitz-Rohmer
-
Publication number: 20240327394Abstract: The present invention relates to compounds of formula (I) or salts, solvates, cocrystals, tautomers, or mixtures thereof. Furthermore, the present invention relates to pharmaceutical compositions comprising said compounds. Moreover, the present invention relates to the compounds of formula (I) or the salts, solvates, cocrystals, tautomers, or mixtures thereof or the pharmaceutical compositions for use as a medicament and to the compounds of formula (I) or the salts, solvates, cocrystals, tautomers, or mixtures thereof or the pharmaceutical compositions for use in the treatment or amelioration of cancer. Optionally, the compounds of formula (I) or the salts, solvates, cocrystals, tautomers, or mixtures thereof or the pharmaceutical compositions are administered in combination with a second therapeutic agent, in particular an anti-cancer agent.Type: ApplicationFiled: April 7, 2022Publication date: October 3, 2024Inventors: Charles-Henry Fabritius, Koen Hekking, Dorothea Gruber, Rutger Folmer, Stefanie Flückiger-Mangual, Thomas Bohnacker, Martin Schwill, Debora Schmitz-Rohmer
-
Publication number: 20230255966Abstract: The present invention is inter alia concerned with a combination of a CBP/p300 bromodomain inhibitor and an EGFR inhibitor for use in the treatment of a patient suffering from NSCLC, wherein the NSCLC exhibits an oncogenic alteration in the EGFR.Type: ApplicationFiled: June 24, 2021Publication date: August 17, 2023Applicant: TOLREMO THERAPEUTICS AGInventors: Stefanie Flückiger-Mangual, Dorothea Gruber, Thomas Bohnacker, Martin Schwill, Debora Schmitz-Rohmer, Charles-Henry Fabritius, Sara Laudato
-
Publication number: 20230233558Abstract: The present invention is inter alia concerned with (i) a combination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for use in the treatment of a patient suffering from cancer, wherein the cancer exhibits an oncogenic alteration in the KRAS; (ii) a kit comprising (a) a pharmaceutical dosage form comprising a CBP/p300 bromodomain inhibitor and (b) a pharmaceutical dosage form comprising a KRAS inhibitor, and (iii) a pharmaceutical dosage form comprising a CBP/p300 bromodomain inhibitor and a a KRAS inhibitor.Type: ApplicationFiled: June 24, 2021Publication date: July 27, 2023Applicant: TOLREMO THERAPEUTICS AGInventors: Stefanie Flückiger-Mangual, Dorothea Gruber, Thomas Bohnacker, Martin Schwill, Debora Schmitz-Rohmer, Charles-Henry Fabritius, Sara Laudato
-
Publication number: 20230226057Abstract: The present invention relates to a compound of formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof and to pharmaceutical compositions comprising a compound of formula (I), as well as to the use of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, in the treatment of fibrotic diseases, preferably idiopathic pulmonary fibrosis (IPF) or non-alcoholic steatohepatitis (NASH). Further aspects of the present invention include combination therapies in which a compound of formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, is used in combination with a known anti-fibrotic or anti-inflammatory agents for fibrotic diseases.Type: ApplicationFiled: June 24, 2021Publication date: July 20, 2023Applicant: TOLREMO THERAPEUTICS AGInventors: Stefanie Flückiger-Mangual, Thomas Bohnacker
-
Publication number: 20220153752Abstract: The invention relates to novel phosphoinositide 3-kinase (PI3K), mammalian target of rapamycin (mTOR) and PI3K-related kinase (PIKKs) inhibitor compounds of formula (I), wherein X1, X2 and X3 are N or CH, with the proviso that at least two of X1, X2 and X3 are N; Y is N or CH, These compounds are useful, either alone or in combination with further therapeutic agents, for treating disorders mediated by lipid kinases.Type: ApplicationFiled: October 12, 2021Publication date: May 19, 2022Inventors: Vladimir CMILJANOVIC, Paul HEBEISEN, Florent BEAUFILS, Thomas BOHNACKER, Denise RAGEOT, Alexander SELE, Matthias WYMANN, Jean-Baptiste LANGLOIS
-
Patent number: 11186591Abstract: The invention relates to novel phosphoinositide 3-kinase (PI3K), mammalian target of rapamycin (mTOR) and PI3K-related kinase (PIKKs) inhibitor compounds of formula (I), wherein X1, X2 and X3 are N or CH, with the proviso that at least two of X1, X2 and X3 are N; Y is N or CH, These compounds are useful, either alone or in combination with further therapeutic agents, for treating disorders mediated by lipid kinases.Type: GrantFiled: March 13, 2020Date of Patent: November 30, 2021Assignees: UNIVERSITÄT BASEL, TORQUR AGInventors: Vladimir Cmiljanovic, Paul Hebeisen, Florent Beaufils, Thomas Bohnacker, Denise Rageot, Alexander Sele, Matthias Wymann, Jean-Baptiste Langlois
-
Publication number: 20200277304Abstract: The invention relates to novel phosphoinositide 3-kinase (PI3K), mammalian target of rapamycin (mTOR) and PI3K-related kinase (PIKKs) inhibitor compounds of formula (I), wherein X1, X2 and X3 are N or CH, with the proviso that at least two of X1, X2 and X3 are N; Y is N or CH, These compounds are useful, either alone or in combination with further therapeutic agents, for treating disorders mediated by lipid kinases.Type: ApplicationFiled: March 13, 2020Publication date: September 3, 2020Inventors: Vladimir CMILJANOVIC, Paul HEBEISEN, Florent BEAUFILS, Thomas BOHNACKER, Denise RAGEOT, Alexander SELE, Matthias WYMANN, Jean-Baptiste LANGLOIS
-
Patent number: 10640516Abstract: The invention relates to novel phosphoinositide 3-kinase (PI3k), mammalian target of rapamycin (mTOR) and PI3k-related kinase (PIKKs) inhibitor compounds of formula (I), wherein X1, X2 and X3 are N or CH, with the proviso that at least two of X1, X2 and X3 are N; Y is N or CH, These compounds are useful, either alone or in combination with further therapeutic agents, for treating disorders mediated by lipid kinases.Type: GrantFiled: November 10, 2015Date of Patent: May 5, 2020Assignees: PIQUR THERAPEUTICS AG, UNIVERSITÄT BASELInventors: Vladimir Cmiljanovic, Paul Hebeisen, Florent Beaufils, Thomas Bohnacker, Denise Rageot, Alexander Sele, Matthias Wymann, Jean-Baptiste Langlois
-
Publication number: 20190031682Abstract: The invention relates to novel phosphoinositide 3-kinase (PI3k), mammalian target of rapamycin (mTOR) and PI3k-related kinase (PIKKs) inhibitor compounds of formula (I), wherein X1, X2 and X3 are N or CH, with the proviso that at least two of X1, X2 and X3 are N; Y is N or CH, These compounds are useful, either alone or in combination with further therapeutic agents, for treating disorders mediated by lipid kinases.Type: ApplicationFiled: November 10, 2015Publication date: January 31, 2019Inventors: Vladimir CMILJANOVIC, Paul HEBEISEN, Florent BEAUFILS, Thomas BOHNACKER, Denise RAGEOT, Alexander SELE, Matthias WYMANN, Jean-Baptiste LANGLOIS
-
Patent number: 9556203Abstract: The invention relates to novel phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor compounds of formula (I) and (II), which are conformationally restricted, and for which the meaning of the substituents are listed in the description. Preferred compounds are those wherein X isoxygen, R1 is morpholino and R2 is substituted phenyl or heteroaryl. These compounds are useful, either alone or in combination with further therapeutic agents, for treating disorders mediated by lipid kinases.Type: GrantFiled: October 3, 2014Date of Patent: January 31, 2017Assignees: PIQUR THERAPEUTICS AG, UNIVERSITAET BASELInventors: Vladimir Cmiljanovic, Paul Hebeisen, Eileen Jackson, Florent Beaufils, Thomas Bohnacker, Matthias Wymann
-
Publication number: 20160244463Abstract: The invention relates to novel phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor compounds of formula (I) and (II), which are conformationally restricted, and for which the meaning of the substituents are listed in the description. Preferred compounds are those wherein X isoxygen, R1 is morpholino and R2 is substituted phenyl or heteroaryl. These compounds are useful, either alone or in combination with further therapeutic agents, for treating disorders mediated by lipid kinases.Type: ApplicationFiled: October 3, 2014Publication date: August 25, 2016Inventors: Vladimir Cmiljanovic, Paul Hebeisen, Eileen Jackson, Florent Beaufils, Thomas Bohnacker, Matthias Wymann